Breast cancers are ER-positive, HER2-positive, or triple negative. The type of breast cancer you have determines the type of medication you take. Learn more from experts at WebMD.
From January 2010 to December 2014, we retrospectively reviewed and analyzed 291 (external validation) and 585 (development cohort) HER2-negative, ER-positive breast cancer patients. Cox regression analysis, both multivariate and univariate, confirmed the independence indicators ...
FULL PAPER British Journal of Cancer (2015) 112, 912–917 | doi: 10.1038/bjc.2014.641 Keywords: breast cancer; survival; adjuvant treatment; risk assessment; predictive models Are we able to predict survival in ER-positive HER2-negative breast cancer? A comparison of web-based models E Laas1...
: This article aims to discuss elacestrant, an oral selective estrogen receptor downregulator approved by the Food and Drug Administration (FDA) in January 2023 for the treatment of hormone receptor positive (HR ) human epidermal growth factor receptor 2 negative (HER2) advanced breast cancer. ...
ER positive, HER2 negative Breast Cancer - Pipeline Insight, 2024 Drug Pipelines 40 Pages April 2024 Global From €985 €1232 Breast Cancer Pipeline Analysis Report Report 150 Pages August 2024 Global From €2462 Human Epidermal Growth Factor Receptor 2 Negative Breast Cancer (Her2- Breast Cancer)...
Hormone receptor-positive (HR+)/human epidermal growth factor receptor 2-negative (HER2−) breast cancer is the most prevalent type of breast cancer, in which endocrine therapy resistance and distant relapse remain unmet challenges. Accurate molecular classification is urgently required for guiding pre...
在接受新辅助化疗的早期乳腺癌患者中,HER2低表达与HER2零表达患者化疗敏感性或预 后无明显差异。提示目前乳腺癌NAC时,无需单独考虑HER2低表达或HER2零表达状态。 参考文献 Ilie SM, Briot N, Constantin G, Roussot N, Ilie A, Ber...
Some subtypes of aggressive breast cancer, like high-grade tumors called triple-negative tumors, are twice as common among Black women, especially younger Black women, as compared to their White peers. These cancers include: ER+ and HER2/neu-positive subtype ER+ and HER2/neu-negative subtype ...
Estrogen receptor-positive, progesterone receptor-negative, and human epidermal growth factor receptor 2 (HER2)-negative (ER+PR-HER2-) breast cancer comprise a special type of breast cancer that constitutes ~10% of all breast cancer patients. ER+PR-HER2- tumor benefits less from endocrine therapy...
12月6日,在2024年欧洲肿瘤内科学会亚洲大会(ESMO ASIA)的“Proffered Paper session: Breast cancer”专场上,上海交通大学医学院附属新华医院的吕文杰教授分享了一项重要研究成果,该研究基于美国国立癌症研究所的SEER数据库,深入探讨了新辅助治疗对70岁及以上HER2阴性乳腺癌患者总生存期(OS)的影响。结果显示,新辅助...